Justin Tyler Moyers MD
Assistant Clinical Professor, Division of Hematology/Oncology, Medicine
School of Medicine
University of California, Irvine

Melanoma treatment have been revolutionized since 2010 by the development of immune checkpoint inhibitors, and, for BRAF-mutated melanoma, targeted therapies based on BRAF and MEK inhibitors, which is a model of effective targeted therapy in cancer. However, patients with BRAF wild type cannot benefit for such treatments.

свернуть